This is one of two pathways that deal with DNA damage. It has two central gene products (ATM and TP53) which are connected with the [[Pathway:WP707|other DNA damage response pathway]]. In this pathway there is only one source of DNA damage induction, since most DNA damage induction sources and their involvement are mentioned in the [[Pathway:WP707|first DNA damage response pathway]]. If it is not mentioned differently, the processes take place in the cell cytoplasm. The purpose of this pathway is to report more gene products and cell condition changes through the DNA damage response pathway and at the same time keep them clearly arranged. Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP710 CPTAC Assay Portal] MOUSE:KG38 MOUSE e6f e6f e6f e6f e6f e6f e6f e6f e6f e6f e6f e6f d17 18004398 PubMed CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nat Rev Cancer 2007 Antoni L Sodha N Collins I Garrett MD 17568790 PubMed CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 2007 Boutros R Lobjois V Ducommun B 17060944 PubMed Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006 Sparmann A van Lohuizen M 15668327 PubMed Chromosomal instability in oral cancer cells. J Dent Res 2005 Reshmi SC Gollin SM 17768402 PubMed Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007 Wang W 20610534 PubMed Beta-catenin (CTNNB1) promotes preovulatory follicular development but represses LH-mediated ovulation and luteinization. Mol Endocrinol 2010 Fan HY O'Connor A Shitanaka M Shimada M Liu Z Richards JS 16805667 PubMed Surviving the breakup: the DNA damage checkpoint. Annu Rev Genet 2006 Harrison JC Haber JE 15339658 PubMed Wagging the dogma; tissue-specific cell cycle control in the mouse embryo. Cell 2004 Pagano M Jackson PK 19111245 PubMed Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale? Lancet Oncol 2009 Chargari C Toillon RA Macdermed D Castadot P Magnأ¯آ؟آ½أ¯آ؟آ½أژآ© N 15545627 PubMed Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004 Sherr CJ Roberts JM 17380161 PubMed p53 in health and disease. Nat Rev Mol Cell Biol 2007 Vousden KH Lane DP 14993903 PubMed Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004 Zhou BB Bartek J 16921403 PubMed Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 2006 Gil J Peters G 17943134 PubMed The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer 2007 Lأ¯آ؟آ½أ¯آ؟آ½أژآ©brich M Jeggo PA p53-dependent G1/S DNA damage checkpoint pathway PW:0000303 Pathway Ontology 15343279 PubMed Transcription - guarding the genome by sensing DNA damage. Nat Rev Cancer 2004 Ljungman M Lane DP p53 signaling pathway PW:0000718 Pathway Ontology 15719025 PubMed The role of BH3-only proteins in the immune system. Nat Rev Immunol 2005 Strasser A 15688066 PubMed p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005 Sengupta S Harris CC 14634621 PubMed The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003 Cory S Huang DC Adams JM